Repligen (NASDAQ:RGEN) Issues Earnings Results

Repligen (NASDAQ:RGEN) issued its earnings results on Tuesday. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09, FiscalAI reports. The company had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.26 EPS. Repligen updated its FY 2026 guidance to 2.030-2.090 EPS.

Here are the key takeaways from Repligen’s conference call:

• Strong Q2 results and raised guidance: Revenue reached $204 million, up 12% reported and 13% organically, while adjusted EPS rose 46% to $0.54. Repligen raised its full-year organic growth outlook to 10.5%–13.5% and adjusted EPS guidance to $2.03–$2.09.
• Broad-based franchise momentum: Proteins grew 50%, Analytics increased more than 30%, and Chromatography delivered low-double-digit growth. Emerging biotech grew at a high-teens rate for the fifth consecutive quarter, suggesting improving customer funding and demand.
• Margin expansion continued: Adjusted operating margin expanded 460 basis points to 16.7%, supported by volume leverage, pricing, product mix, and manufacturing efficiencies. The company raised full-year operating margin guidance to 15.7%–16% while remaining on track for its 30% adjusted EBITDA margin target by 2030.
• BioLife acquisition expected to add growth and earnings: Management said the planned acquisition will accelerate Repligen’s cell-therapy strategy and add at least $20 million of synergies and $0.05 of adjusted EPS accretion in year one, rising to at least $30 million and $0.25 in year two. The transaction is not included in current 2026 guidance and remains subject to customary approvals.
• Filtration remains a near-term weak spot: Filtration revenue grew only slightly as gene-therapy exposure, customer inventory reductions, site-readiness delays, and the Polymem divestiture weighed on results. Management expects some of these pressures to persist into Q3, although ATF order momentum and normalization are anticipated in Q4 and 2027.

Repligen Stock Up 10.9%

Shares of NASDAQ:RGEN opened at $145.34 on Wednesday. The company has a market capitalization of $8.20 billion, a price-to-earnings ratio of 161.49, a PEG ratio of 2.53 and a beta of 1.06. Repligen has a 12-month low of $100.99 and a 12-month high of $175.77. The business has a 50-day moving average price of $132.95 and a 200 day moving average price of $131.88. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RGEN. Royal Bank Of Canada started coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target on the stock. Canaccord Genuity Group cut their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group restated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $165.36.

Insider Buying and Selling

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the 3rd quarter worth approximately $29,000. Los Angeles Capital Management LLC purchased a new stake in Repligen in the fourth quarter valued at approximately $36,000. Itau Unibanco Holding S.A. raised its position in Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares during the period. Johnson Financial Group Inc. acquired a new position in Repligen during the third quarter worth $65,000. Finally, Wilmington Savings Fund Society FSB lifted its stake in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q2 beat expectations: Revenue rose 12% year over year to $204.1 million, exceeding the approximately $201.6 million consensus estimate. Adjusted EPS was $0.54, well above the $0.45 analyst expectation and up from $0.37 a year earlier. Repligen Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Growth and margins improved: Organic revenue growth reached 13%, while adjusted operating income increased 55% to $34 million. Adjusted operating margin expanded to 16.7% from 12.0% in the prior-year quarter, suggesting stronger operating leverage. Repligen Q2 2026 Financial Results
• Positive Sentiment: Guidance was raised: Repligen now expects 2026 organic revenue growth of 10.5% to 13.5% and adjusted EPS of $2.03 to $2.09, above the roughly $2.00 consensus EPS estimate. Reported revenue guidance is $813 million to $835 million. Management cited strong first-half performance, order momentum and better visibility into the second half.
• Positive Sentiment: BioLife Solutions acquisition adds strategic appeal: Management said the pending acquisition should strengthen Repligen’s cell-therapy position and be accretive to revenue growth, margins and adjusted EPS over time. The deal remains subject to completion and integration risks.
• Neutral Sentiment: Analyst support: William Blair maintained a Buy rating, citing the earnings beat, higher guidance and broad-based demand strength. However, the stock’s valuation remains elevated, with a reported price-to-earnings ratio above 160.
• Negative Sentiment: GAAP profitability weakened: Net income fell to $5.0 million from $14.9 million, and GAAP diluted EPS declined to $0.09 from $0.26. The decline reflected higher taxes and other expenses, despite stable GAAP operating income and stronger non-GAAP results.
• Negative Sentiment: Insider selling is a modest caution: CEO Olivier Loeillot and CFO Jason Garland reportedly sold shares during the past six months, with no disclosed insider purchases.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.